Wiebke Antonia Löbker

Dr. Wiebke Antonia Löbker

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Drug Discovery Today
Verified
Journal Article
Open access
VSViktoriia Starokozhko
Viktoriia Starokozhko
MKMarko Kallio
Marko Kallio
ÅHÅsa Kumlin Howell
Åsa Kumlin Howell
ASAnna Mäkinen Salmi
Anna Mäkinen Salmi
GAGunilla Andrew-Nielsen
Gunilla Andrew-Nielsen
PMPeter G.M. Mol
Peter G.M. Mol
Truly disruptive medicine innovation and new treatment paradigms tend to start in non-commercial research institutions. However, the lack of mutual understanding between medicine developers and regulators when it comes to medicine development significantly delays or even prevents the access of patients to these innovations. Here, we outline what regulatory-related barriers hamper the translational development of novel products or new treatment paradigms initiated in academia, and propose key steps towards improved regulatory dialogue among academia, funding bodies and regulatory authorities. Moreover, we briefly describe how the STARS (Strengthening Training of Academia in Regulatory Science) project aims to reach out to medicine innovators in academia to bridge the regulatory knowledge gap and enhance this dialogue to facilitate the implementation of academic research findings in clinical practice.

5 October 2021 in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Verified
Journal Article
Open access
PDF file
WLWolfgang Lauer
Wolfgang Lauer
WLWiebke Antonia Löbker
Wiebke Antonia Löbker
TSThomas Sudhop
Thomas Sudhop
Karl BroichKarl Broich
Karl Broich

21 November 2022 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
MKMarko J. Kallio
Marko J. Kallio
VSViktoriia Starokozhko
Viktoriia Starokozhko
EAEleonora Agricola
Eleonora Agricola
MBManja Burggraf
Manja Burggraf
AHAnne Heß
Anne Heß
TCthe STARS consortium
the STARS consortium
Important discoveries by academic drug developers hold the promise of bringing innovative treatments that address unmet medical needs to the market. However, the drug development process has proved to be challenging and demanding for academic researchers, and regulatory challenges are an important barrier to implementing academic findings in clinical practice. European regulators offer varying degrees of support services to help drug developers meet regulatory standards and requirements. “Strengthening Training of Academia in Regulatory Sciences and Supporting Regulatory Scientific Advice” (STARS) is a European Commission–funded consortium aiming to strengthen the training of academics in regulatory science and requirements. Here, we report the results of four surveys that investigated the awareness and utilization of support tools offered by European regulators and identified the regulatory challenges and support needs of researchers. The surveys targeted four main European stakeholders in academic medicines research: academic research groups (706 respondents), academic research centers (99), funding organizations (49), and regulators (22). The results show that while European regulators provide various regulatory support tools, less than half of the responding academic researchers were aware of these tools and many experienced challenges in reaching a sufficient level of regulatory knowledge. There was a general lack of understanding of the regulatory environment that was aggravated by poor communication between stakeholders. The results of this study form a foundation for an improved European medicines regulatory network, in which regulatory challenges faced by academia are tackled.

15 September 2021 in Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
Verified
Journal Article
Open access
PDF file
KBKarl Broich
Karl Broich
WLWiebke Antonia Löbker
Wiebke Antonia Löbker
WLWolfgang Lauer
Wolfgang Lauer
Zusammenfassung: Die Digitalisierung stellt auch im Gesundheitsbereich einen eindeutigen Megatrend dar, der neben der Wegbereitung durch geänderte rechtliche Rahmenbedingungen auch durch die Coronapandemie eine enorme Beschleunigung erfahren hat. Mit Blick in die Zukunft wird dieser Trend durch immer kürzere Entwicklungszyklen und technologischen Fortschritt zu einer zunehmenden Verschmelzung einzelner digitaler und nicht digitaler Produkte, darunter Arzneimittel und digitale Medizinprodukte, zu einem digitalen Ökosystem beitragen. Die Digitalisierung wird nicht nur die Patientensouveränität stärken, sondern unter anderem auch eine patientenzentrierte, stärker auf den individuellen Patienten ausgerichtete Medizin ermöglichen; digitale (patientenberichtete) Endpunkte und „dezentrale“ Studienkonzepte werden die Möglichkeiten klinischer Studien erweitern. Künstliche Intelligenz wird Diagnosestellungen verbessern und beschleunigen und zum besseren Verständnis von Krankheitsbildern beitragen.Um auch zukünftig Innovationen zu ermöglichen, aufkommende Trends im Fokus zu haben und vor allem die Patientensicherheit weiter zu verbessern, trägt das Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) an vielen Stellen dazu bei, die mit der Digitalisierung verbundenen Chancen in Möglichkeiten zu verwandeln – ohne dabei die Risiken aus dem Blick zu verlieren: Dazu gehören der Ausbau des Forschungsdatenzentrums, Aufgaben zu Interoperabilität und Klassifikationen sowie Ansätze zur datengestützten Signalerkennung aus Risikoinformationen. Wie darüber hinaus Forschungsprojekte unter Nutzung von künstlicher Intelligenz, (inter)nationale Kooperationen, die Einbeziehung von Real World Data in Nutzen-Risiko-Bewertungen, die Bewertung digitaler Gesundheits- und Pflegeanwendungen neben weiteren Aktivitäten zur „digital readiness“ in Deutschland und Europa beitragen, dazu im Folgenden ein Überblick.

Verified
Journal Article
Open access
PDF file
Karl BroichKarl Broich
Karl Broich
WLWiebke Antonia Löbker
Wiebke Antonia Löbker
The harmonization of pharmaceutical regulations within the European Union has been a crucial step towards ensuring high safety standards and efficient access to innovative medicines. The evolution from fragmented national regulations to a unified legal framework has streamlined the marketing authorization process, fostered scientific collaboration, and reduced administrative burdens. The establishment of the centralized marketing authorization procedure and the European Medicines Agency (EMA) has played a pivotal role in coordinating regulatory efforts across member states. This article examines the historical developments, regulatory milestones, and the impact of harmonization on pharmaceutical assessments. Furthermore, it explores key lessons learned—including the value of centralized coordination, standardization, capacity and knowledge-sharing, transparency and trust—from the regulatory landscape that could inform the evolving Health Technology Assessment (HTA) framework in the EU.